57 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
56
Ending by 2030
Nov 2026
Next term end
18
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2027 · High confidence
Also notable
Ends Jan 2027 · High confidence
Also notable
Ends Jan 2027 · High confidence
Antagonists to IL-17A, IL-17F, and IL-23P19 and Methods of Use
US 7,910,703
Cited by 39 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells with IL-31 Antagonists
US 7,514,077
The most cited patent in this portfolio, cited by 54 later US patents, top 25% of utility patents granted in 2009 in our data. Protection runs to 2027.
Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb
US 7,638,126
The most cited patent in this portfolio, cited by 54 later US patents, top 25% of utility patents granted in 2009 in our data. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 29, 2027The maintenance fee for Levels of Blys/April Heterotrimers in Serum and Use in Diagnostic Methods (US 9,146,242) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Soluble Hybrid Fcgamma Receptors and Related Methods (US 10,570,187) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Nucleic Acid Molecules Encoding Humanized IL-31 Monoclonal Antibodies (US 10,640,559) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 18 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Antibodies That Bind Both IL-17A and IL-17F and Methods of Using the Same | 13 in force | to Jan 2028 |
| Humanized Antibody Molecules Specific for IL-31 | 8 in force | to Jul 2030 |
| Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells with IL-31 Antagonists | 6 in force | to Jan 2027 |
| Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb | 6 in force | to Jan 2027 |
| Anti-Human IL-21 Monoclonal Antibodies | 4 in force | to Dec 2028 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,592,427 | Antibodies to IL-21 Receptor In force · High confidence | In force | High confidence | |
| US 7,514,077 | Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells with IL-31 Antagonists In force · High confidence | In force | High confidence | |
| US 7,638,126 | Methods of Treating Pain and Inflammation in Neuronal Tissue Using Antagonists of IL-31, IL-31RA And/Or Osmrb In force · High confidence | In force | High confidence | |
| US 8,637,015 | Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells In force · Low confidence | In force | Low confidence | |
| US 8,685,395 | Methods of Antagonizing Signal Transduction in Dorsal Root Ganglion Cells In force · Low confidence | In force | Low confidence | |
| US 8,968,732 | Methods of Treating Pain Using an IL-31 Monoclonal Antibody In force · Medium confidence | In force | Medium confidence | |
| US 8,974,783 | Methods of Treating Pain Using an IL-31RA or Osmr-B Antagonist In force · Low confidence | In force | Low confidence | |
| US 9,334,321 | Methods of Treating Neuronal Inflammation Using an IL-31 Monoclonal Antibody In force · Low confidence | In force | Low confidence | |
| US 9,334,322 | Methods of Antagonizing Signal Transduction in Spinal Cord Cells Using an IL-31RA or Osmr-B Antagonist In force · Medium confidence | In force | Medium confidence | |
| US 9,631,021 | Use of an IL-31 Monoclonal Antibody for Antagonizing Signal Transduction in Spinal Cord Cells In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 57: 5 patents in force now held by others · 129 patents ended · 1 application pending · 169 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.